MGI(SH:688114) Xin Lang Cai Jing·2026-01-29 02:33Group 1 - The core viewpoint of the news is that BGI Genomics has seen a 5% increase in stock price, reaching 69.30 CNY per share, with a trading volume of 145 million CNY and a turnover rate of 0.51%, resulting in a total market capitalization of 28.865 billion CNY [1] - BGI Genomics, established on April 13, 2016, and listed on September 9, 2022, focuses on the life sciences and biotechnology sectors, primarily engaged in the research, production, and sales of instruments, equipment, and consumables [1] - The main revenue composition of BGI Genomics includes 90.89% from sales of instruments and consumables, 7.10% from services, and 2.01% from other sources [1] Group 2 - Among the top circulating shareholders of BGI Genomics, E Fund's fund holds a significant position, having reduced its holdings by 1.0979 million shares in the third quarter, now owning 7.5258 million shares, which accounts for 1.82% of the circulating shares [2] - E Fund's Shanghai Stock Exchange Sci-Tech Innovation Board 50 ETF (588080) has a current scale of 70.597 billion CNY and has achieved a year-to-date return of 15.66%, ranking 502 out of 5551 in its category [2] - The fund has a one-year return of 63.58%, ranking 718 out of 4285 in its category, and a total return since inception of 12.14% [2] Group 3 - The fund managers of E Fund's Shanghai Stock Exchange Sci-Tech Innovation Board 50 ETF are Lin Weibin and Cheng Xi, with Lin having a tenure of 12 years and 333 days and a total fund asset size of 119.408 billion CNY [3] - Lin's best fund return during his tenure is 82.52%, while the worst is -22.14% [3] - Cheng has a tenure of 9 years and 270 days, managing a total fund asset size of 236.954 billion CNY, with a best return of 131.04% and a worst return of -67.89% during his tenure [3]